#United States #Los Angeles #Autism #Spinogenix #Craig Erickson

Spinogenix Honors Dr. Craig Erickson with a $17.25 Million Grant for Autism Research

Spinogenix, Inc., a prominent clinical-stage biopharmaceutical enterprise, has proclaimed its recognition of Dr. Craig Erickson, the Chief Medical Advisor, in light of a substantial $17.25 million grant awarded to Cincinnati Children's Hospital. This grant, stemming from the Aligning Research to Impact Autism (ARIA) initiative, marks a significant step forward in autism research and treatment.

The grant specifically acknowledges Dr. Erickson's groundbreaking research in Fragile X syndrome (FXS) and autism, which has been a focal point of his work for over two decades. Recently, Dr. Erickson led a Phase 2a study evaluating SPG601, a novel treatment for FXS, allowing the public to glean insights into the future of autism therapeutics.

As part of the funding, Cincinnati Children's Hospital will collaborate with a global network, known as Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT). This initiative is noteworthy as one of only ten global sites selected to participate in this endeavor. The IMPACT network is charged with creating a comprehensive repository of deep medical data related to individuals living with autism. The culmination of this data aims to enhance clinical trials, leading to innovative treatment exploration.

Dr. Erickson will take on the role of principal investigator for the hospital's involvement in IMPACT. His studies will explore how electroencephalogram (EEG) technology can be utilized to refine the understanding of each child's biological framework. The output will ultimately direct the development of precision medicines tailored for autism spectrum disorder.

Dr. Stella Sarraf, CEO and Founder of Spinogenix, conveyed her appreciation for Dr. Erickson's contributions. "Craig's leadership has cemented our understanding of autism and improved countless lives," she stated. "This notable grant showcases his scientific expertise and dedication to furthering precision medicine for neurodevelopmental disorders."

In the United States, autism spectrum disorder affects 1 in 31 children and roughly 1 in 45 adults, according to data from the Centers for Disease Control and Prevention. As researchers delve deeper into the multifaceted nature of autism, they increasingly recognize the necessity for individualized therapeutic strategies.

Dr. Erickson commented on the potential of this initiative: "This opportunity could significantly enhance our comprehension of autism's specific etiologies. By integrating EEG biomarkers, genomic analysis, and extensive longitudinal phenotyping, we will be better equipped to lay the groundwork for future clinical trials. Ultimately, it will illuminate which patients stand to gain the most from emerging therapies while ensuring that our research captures the full spectrum of autism's diversity."

About Spinogenix

Established with a mission to redefine the treatment landscape for neurodegenerative, neuropsychiatric, and neurodevelopmental conditions, Spinogenix is dedicated to advancing first-in-class therapeutics designed to restore synaptic functionality. Current treatment options primarily focus on alleviating symptoms or slowing disease progression, often leaving patients without prospects for true advancement in their health.

Spinogenix is in the process of developing two groundbreaking therapeutics: Tazbentetol (SPG302), aimed at inducing neurons to generate new glutamatergic synapses for conditions such as ALS, Alzheimer's disease, and schizophrenia; and SPG601, which targets specific dysfunctions in Fragile X Syndrome that underpin many of its core symptoms. The company has garnered Orphan Drug designations from both the FDA and EMA for Tazbentetol concerning ALS, alongside FDA Orphan Drug status and Fast Track designations for SPG601 targeting FXS.

For further details regarding Spinogenix and its innovative efforts, please visit spinogenix.com or follow them on LinkedIn.